Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults
Abstract Background We compared homologous and heterologous boosting in adults in the Philippines primed with 2 or 3 doses of CoronaVac, with recombinant protein vaccine, SCB-2019. Methods CoronaVac-immunized adults (18–72 years) received a homologous or heterologous full or half dose SCB-2019 boost...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 2023-11, Vol.228 (9), p.1253-1262 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1262 |
|---|---|
| container_issue | 9 |
| container_start_page | 1253 |
| container_title | The Journal of infectious diseases |
| container_volume | 228 |
| creator | Roa, Camilo C de Los Reyes, Mari Rose A Plennevaux, Eric Smolenov, Igor Hu, Branda Gao, Faith Ilagan, Hannalyn Ambrosino, Donna Siber, George Clemens, Ralf |
| description | Abstract
Background
We compared homologous and heterologous boosting in adults in the Philippines primed with 2 or 3 doses of CoronaVac, with recombinant protein vaccine, SCB-2019.
Methods
CoronaVac-immunized adults (18–72 years) received a homologous or heterologous full or half dose SCB-2019 booster. We assessed all neutralizing antibody (NAb) responses against prototype SARS-CoV-2 after 15 days and NAb against SARS-CoV-2 Delta and Omicron variants in subsets (30‒50 per arm). Participants recorded adverse events.
Results
In 2-dose CoronaVac-primed adults prototype NAb geometric mean titers (GMT) were 203 IU/mL (95% confidence interval [CI], 182–227) and 939 IU/mL (95% CI, 841–1049) after CoronaVac and SCB-2019 boosters; the GMT ratio (4.63; 95% CI, 3.95–5.41) met predefined noninferiority and post-hoc superiority criteria. After 3-dose CoronaVac-priming prototype NAb GMTs were 279 IU/mL (95% CI, 240–325), 1044 IU/mL (95% CI, 898–1213), and 668 IU/mL (95% CI, 520–829) following CoronaVac, full and half-dose SCB-2019 boosters, respectively. NAb GMT ratios against Delta and Omicron comparing SCB-2019 with CoronaVac were all greater than 2. Mild to moderate reactogenicity was evenly balanced between groups. No vaccine-related serious adverse events were reported.
Conclusions
Full or half dose SCB-2019 boosters were well tolerated with superior immunogenicity than homologous CoronaVac, particularly against newly emerged variants.
Clinical Trials Registration. NCT05188677.
We compared heterologous boosting with SCB-2019 recombinant protein vaccine with homologous boosting in adults primed with 2–3 doses of CoronaVac vaccine. Heterologous boosting elicited superior neutralizing antibody responses against prototype SARS-CoV-2 and Delta and Omicron variants than homologous boosting. |
| doi_str_mv | 10.1093/infdis/jiad262 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10629704</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/infdis/jiad262</oup_id><sourcerecordid>3039881290</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-dff6f3e213ed740e4113d7d2f79ed85ffeeb9f9c8cfde82ccb97f604b161297b3</originalsourceid><addsrcrecordid>eNqFkc1uEzEUhS0EoiGwZYkssYHFtP6ZjMcrlEZAkCqKSOnW8tjXwdHETu2ZSuVpeFQcklbAhpVl-fO595yD0EtKTimR_MwHZ30-23htWcMeoQmdcVE1DeWP0YQQxiraSnmCnuW8IYTUvBFP0QkXNZeC0An6uRp3kHxM-DzGPPiwxtHhzzAOSff-x_5-5QdIGc_X2oc84MutNykGvJp_XVWLeF0xfK2T12HIuLvDSyh07OM6jhmvFucVI1QWwhgfAN9mrPEybu-B30MhYR_wIhZVXcDqS_JbsHhux37Iz9ETp_sML47nFH378P5qsawuLj9-WswvKlPP-FBZ5xrHgVEOVtQEakq5FZY5IcG2M-cAOumkaY2z0DJjOilcQ-qONpRJ0fEpenfQ3Y1dmW4g7BNQu7KLTncqaq_-fgn-u1rHW0VJUwRKslP05qiQ4s0IeVBbnw30vQ5QvCrW8qYVrSwNTdHrf9BNHFMo_hQnXLZt2YkU6vRAlbxzTuAetqFE7dtXh_bVsf3y4dWfHh7w-7oL8PYAxHH3P7Ff7_e-Sg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3039881290</pqid></control><display><type>article</type><title>Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Roa, Camilo C ; de Los Reyes, Mari Rose A ; Plennevaux, Eric ; Smolenov, Igor ; Hu, Branda ; Gao, Faith ; Ilagan, Hannalyn ; Ambrosino, Donna ; Siber, George ; Clemens, Ralf</creator><creatorcontrib>Roa, Camilo C ; de Los Reyes, Mari Rose A ; Plennevaux, Eric ; Smolenov, Igor ; Hu, Branda ; Gao, Faith ; Ilagan, Hannalyn ; Ambrosino, Donna ; Siber, George ; Clemens, Ralf</creatorcontrib><description>Abstract
Background
We compared homologous and heterologous boosting in adults in the Philippines primed with 2 or 3 doses of CoronaVac, with recombinant protein vaccine, SCB-2019.
Methods
CoronaVac-immunized adults (18–72 years) received a homologous or heterologous full or half dose SCB-2019 booster. We assessed all neutralizing antibody (NAb) responses against prototype SARS-CoV-2 after 15 days and NAb against SARS-CoV-2 Delta and Omicron variants in subsets (30‒50 per arm). Participants recorded adverse events.
Results
In 2-dose CoronaVac-primed adults prototype NAb geometric mean titers (GMT) were 203 IU/mL (95% confidence interval [CI], 182–227) and 939 IU/mL (95% CI, 841–1049) after CoronaVac and SCB-2019 boosters; the GMT ratio (4.63; 95% CI, 3.95–5.41) met predefined noninferiority and post-hoc superiority criteria. After 3-dose CoronaVac-priming prototype NAb GMTs were 279 IU/mL (95% CI, 240–325), 1044 IU/mL (95% CI, 898–1213), and 668 IU/mL (95% CI, 520–829) following CoronaVac, full and half-dose SCB-2019 boosters, respectively. NAb GMT ratios against Delta and Omicron comparing SCB-2019 with CoronaVac were all greater than 2. Mild to moderate reactogenicity was evenly balanced between groups. No vaccine-related serious adverse events were reported.
Conclusions
Full or half dose SCB-2019 boosters were well tolerated with superior immunogenicity than homologous CoronaVac, particularly against newly emerged variants.
Clinical Trials Registration. NCT05188677.
We compared heterologous boosting with SCB-2019 recombinant protein vaccine with homologous boosting in adults primed with 2–3 doses of CoronaVac vaccine. Heterologous boosting elicited superior neutralizing antibody responses against prototype SARS-CoV-2 and Delta and Omicron variants than homologous boosting.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jiad262</identifier><identifier>PMID: 37439701</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Adverse events ; Clinical trials ; COVID-19 vaccines ; Immunogenicity ; Major ; Severe acute respiratory syndrome coronavirus 2 ; Vaccines</subject><ispartof>The Journal of infectious diseases, 2023-11, Vol.228 (9), p.1253-1262</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2023</rights><rights>The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-dff6f3e213ed740e4113d7d2f79ed85ffeeb9f9c8cfde82ccb97f604b161297b3</citedby><cites>FETCH-LOGICAL-c453t-dff6f3e213ed740e4113d7d2f79ed85ffeeb9f9c8cfde82ccb97f604b161297b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,1584,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37439701$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roa, Camilo C</creatorcontrib><creatorcontrib>de Los Reyes, Mari Rose A</creatorcontrib><creatorcontrib>Plennevaux, Eric</creatorcontrib><creatorcontrib>Smolenov, Igor</creatorcontrib><creatorcontrib>Hu, Branda</creatorcontrib><creatorcontrib>Gao, Faith</creatorcontrib><creatorcontrib>Ilagan, Hannalyn</creatorcontrib><creatorcontrib>Ambrosino, Donna</creatorcontrib><creatorcontrib>Siber, George</creatorcontrib><creatorcontrib>Clemens, Ralf</creatorcontrib><title>Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Abstract
Background
We compared homologous and heterologous boosting in adults in the Philippines primed with 2 or 3 doses of CoronaVac, with recombinant protein vaccine, SCB-2019.
Methods
CoronaVac-immunized adults (18–72 years) received a homologous or heterologous full or half dose SCB-2019 booster. We assessed all neutralizing antibody (NAb) responses against prototype SARS-CoV-2 after 15 days and NAb against SARS-CoV-2 Delta and Omicron variants in subsets (30‒50 per arm). Participants recorded adverse events.
Results
In 2-dose CoronaVac-primed adults prototype NAb geometric mean titers (GMT) were 203 IU/mL (95% confidence interval [CI], 182–227) and 939 IU/mL (95% CI, 841–1049) after CoronaVac and SCB-2019 boosters; the GMT ratio (4.63; 95% CI, 3.95–5.41) met predefined noninferiority and post-hoc superiority criteria. After 3-dose CoronaVac-priming prototype NAb GMTs were 279 IU/mL (95% CI, 240–325), 1044 IU/mL (95% CI, 898–1213), and 668 IU/mL (95% CI, 520–829) following CoronaVac, full and half-dose SCB-2019 boosters, respectively. NAb GMT ratios against Delta and Omicron comparing SCB-2019 with CoronaVac were all greater than 2. Mild to moderate reactogenicity was evenly balanced between groups. No vaccine-related serious adverse events were reported.
Conclusions
Full or half dose SCB-2019 boosters were well tolerated with superior immunogenicity than homologous CoronaVac, particularly against newly emerged variants.
Clinical Trials Registration. NCT05188677.
We compared heterologous boosting with SCB-2019 recombinant protein vaccine with homologous boosting in adults primed with 2–3 doses of CoronaVac vaccine. Heterologous boosting elicited superior neutralizing antibody responses against prototype SARS-CoV-2 and Delta and Omicron variants than homologous boosting.</description><subject>Adverse events</subject><subject>Clinical trials</subject><subject>COVID-19 vaccines</subject><subject>Immunogenicity</subject><subject>Major</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccines</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNqFkc1uEzEUhS0EoiGwZYkssYHFtP6ZjMcrlEZAkCqKSOnW8tjXwdHETu2ZSuVpeFQcklbAhpVl-fO595yD0EtKTimR_MwHZ30-23htWcMeoQmdcVE1DeWP0YQQxiraSnmCnuW8IYTUvBFP0QkXNZeC0An6uRp3kHxM-DzGPPiwxtHhzzAOSff-x_5-5QdIGc_X2oc84MutNykGvJp_XVWLeF0xfK2T12HIuLvDSyh07OM6jhmvFucVI1QWwhgfAN9mrPEybu-B30MhYR_wIhZVXcDqS_JbsHhux37Iz9ETp_sML47nFH378P5qsawuLj9-WswvKlPP-FBZ5xrHgVEOVtQEakq5FZY5IcG2M-cAOumkaY2z0DJjOilcQ-qONpRJ0fEpenfQ3Y1dmW4g7BNQu7KLTncqaq_-fgn-u1rHW0VJUwRKslP05qiQ4s0IeVBbnw30vQ5QvCrW8qYVrSwNTdHrf9BNHFMo_hQnXLZt2YkU6vRAlbxzTuAetqFE7dtXh_bVsf3y4dWfHh7w-7oL8PYAxHH3P7Ff7_e-Sg</recordid><startdate>20231102</startdate><enddate>20231102</enddate><creator>Roa, Camilo C</creator><creator>de Los Reyes, Mari Rose A</creator><creator>Plennevaux, Eric</creator><creator>Smolenov, Igor</creator><creator>Hu, Branda</creator><creator>Gao, Faith</creator><creator>Ilagan, Hannalyn</creator><creator>Ambrosino, Donna</creator><creator>Siber, George</creator><creator>Clemens, Ralf</creator><general>Oxford University Press</general><scope>TOX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20231102</creationdate><title>Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults</title><author>Roa, Camilo C ; de Los Reyes, Mari Rose A ; Plennevaux, Eric ; Smolenov, Igor ; Hu, Branda ; Gao, Faith ; Ilagan, Hannalyn ; Ambrosino, Donna ; Siber, George ; Clemens, Ralf</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-dff6f3e213ed740e4113d7d2f79ed85ffeeb9f9c8cfde82ccb97f604b161297b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adverse events</topic><topic>Clinical trials</topic><topic>COVID-19 vaccines</topic><topic>Immunogenicity</topic><topic>Major</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roa, Camilo C</creatorcontrib><creatorcontrib>de Los Reyes, Mari Rose A</creatorcontrib><creatorcontrib>Plennevaux, Eric</creatorcontrib><creatorcontrib>Smolenov, Igor</creatorcontrib><creatorcontrib>Hu, Branda</creatorcontrib><creatorcontrib>Gao, Faith</creatorcontrib><creatorcontrib>Ilagan, Hannalyn</creatorcontrib><creatorcontrib>Ambrosino, Donna</creatorcontrib><creatorcontrib>Siber, George</creatorcontrib><creatorcontrib>Clemens, Ralf</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roa, Camilo C</au><au>de Los Reyes, Mari Rose A</au><au>Plennevaux, Eric</au><au>Smolenov, Igor</au><au>Hu, Branda</au><au>Gao, Faith</au><au>Ilagan, Hannalyn</au><au>Ambrosino, Donna</au><au>Siber, George</au><au>Clemens, Ralf</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2023-11-02</date><risdate>2023</risdate><volume>228</volume><issue>9</issue><spage>1253</spage><epage>1262</epage><pages>1253-1262</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Abstract
Background
We compared homologous and heterologous boosting in adults in the Philippines primed with 2 or 3 doses of CoronaVac, with recombinant protein vaccine, SCB-2019.
Methods
CoronaVac-immunized adults (18–72 years) received a homologous or heterologous full or half dose SCB-2019 booster. We assessed all neutralizing antibody (NAb) responses against prototype SARS-CoV-2 after 15 days and NAb against SARS-CoV-2 Delta and Omicron variants in subsets (30‒50 per arm). Participants recorded adverse events.
Results
In 2-dose CoronaVac-primed adults prototype NAb geometric mean titers (GMT) were 203 IU/mL (95% confidence interval [CI], 182–227) and 939 IU/mL (95% CI, 841–1049) after CoronaVac and SCB-2019 boosters; the GMT ratio (4.63; 95% CI, 3.95–5.41) met predefined noninferiority and post-hoc superiority criteria. After 3-dose CoronaVac-priming prototype NAb GMTs were 279 IU/mL (95% CI, 240–325), 1044 IU/mL (95% CI, 898–1213), and 668 IU/mL (95% CI, 520–829) following CoronaVac, full and half-dose SCB-2019 boosters, respectively. NAb GMT ratios against Delta and Omicron comparing SCB-2019 with CoronaVac were all greater than 2. Mild to moderate reactogenicity was evenly balanced between groups. No vaccine-related serious adverse events were reported.
Conclusions
Full or half dose SCB-2019 boosters were well tolerated with superior immunogenicity than homologous CoronaVac, particularly against newly emerged variants.
Clinical Trials Registration. NCT05188677.
We compared heterologous boosting with SCB-2019 recombinant protein vaccine with homologous boosting in adults primed with 2–3 doses of CoronaVac vaccine. Heterologous boosting elicited superior neutralizing antibody responses against prototype SARS-CoV-2 and Delta and Omicron variants than homologous boosting.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>37439701</pmid><doi>10.1093/infdis/jiad262</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 2023-11, Vol.228 (9), p.1253-1262 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10629704 |
| source | Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Adverse events Clinical trials COVID-19 vaccines Immunogenicity Major Severe acute respiratory syndrome coronavirus 2 Vaccines |
| title | Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T19%3A40%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Superior%20Boosting%20of%20Neutralizing%20Titers%20Against%20Omicron%20SARS-CoV-2%20Variants%20by%20Heterologous%20SCB-2019%20Vaccine%20vs%20a%20Homologous%20Booster%20in%20CoronaVac-Primed%20Adults&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Roa,%20Camilo%20C&rft.date=2023-11-02&rft.volume=228&rft.issue=9&rft.spage=1253&rft.epage=1262&rft.pages=1253-1262&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/jiad262&rft_dat=%3Cproquest_pubme%3E3039881290%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3039881290&rft_id=info:pmid/37439701&rft_oup_id=10.1093/infdis/jiad262&rfr_iscdi=true |